


## PHARMACEUTICAL 2023



## Mirati Therapeutics Inc. Rank 166 of 446





## PHARMACEUTICAL 2023



## Mirati Therapeutics Inc. Rank 166 of 446

The relative strengths and weaknesses of Mirati Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Mirati Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 74% points. The greatest weakness of Mirati Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 34% points.

The company's Economic Capital Ratio, given in the ranking table, is 137%, being 94% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	1,108,961
Cost of Goods Sold	0
Intangible Assets	14,914
Liabilities, Current	159,448
Liabilities, Non-Current	46,683
Other Assets	61,232
Other Compr. Net Income	-12,787
Other Expenses	1,108
Other Liabilities	0
Other Net Income	19,230
Other Revenues	12,436
Property and Equipment	17,540
Research and Development	531,627
Selling, General and Administrative Expense	239,798

Output Variable	Value in 1000 USD
Assets	1,202,647
Liabilities	206,131
Expenses	772,533
Revenues	12,436
Stockholders Equity	996,516
Net Income	-740,867
Comprehensive Net Income	-747,260
Economic Capital Ratio	137%

